Rabeprazole | CAS#117976-89-3 | Proton pump inhibitor

MedKoo Cat#: 527039 | Name: Rabeprazole

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Rabeprazole is an inhibitor of H(+)-K(+)-exchanging atpase in gastric parietal cells. Rabeprazole inhibited CYP3A4 enzyme activity in rCYP3A4 baculosomes with a 50-60% inhibition at 30 muM.

Chemical Structure

Rabeprazole

CAS#117976-89-3

Theoretical Analysis

MedKoo Cat#: 527039

Name: Rabeprazole

CAS#: 117976-89-3

Chemical Formula: C18H21N3O3S

Exact Mass: 359.1304

Molecular Weight: 359.44

Elemental Analysis: C, 60.15; H, 5.89; N, 11.69; O, 13.35; S, 8.92

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 350.00	2 weeks
25mg	USD 640.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Rabeprazole

IUPAC/Chemical Name

2-[[4-(3-Methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole

InChi Key

YREYEVIYCVEVJK-UHFFFAOYSA-N

InChi Code

InChI=1S/C18H21N3O3S/c1-13-16(19-9-8-17(13)24-11-5-10-23-2)12-25(22)18-20-14-6-3-4-7-15(14)21-18/h3-4,6-9H,5,10-12H2,1-2H3,(H,20,21)

SMILES Code

O=S(C1=NC2=CC=CC=C2N1)CC3=NC=CC(OCCCOC)=C3C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Rabeprazole is a proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis and acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM.

In vitro activity:

This study found that rabeprazole can attenuate the cell viability of human gastric cancer cells by inactivating the ERK1/2 signaling pathway. These results demonstrate that since rabeprazole inhibits the viability of gastric cancer cells in vitro, it may serve as a novel antineoplastic agent. Reference: Oncol Lett. 2014 Oct;8(4):1739-1744. https://pubmed.ncbi.nlm.nih.gov/25202402/

In vivo activity:

Rabeprazole has no influence on the antitumor effect of cisplatin. Rabeprazole attenuates cisplatin -induced nephrotoxicity mainly through inhibiting OCT2-mediated cisplatin uptake, without interfering with its anti-tumor property of inducing apoptosis and necroptosis. Reference: Biochem Biophys Res Commun. 2022 Jul 5;612:91-98. https://pubmed.ncbi.nlm.nih.gov/35512462/

	Solvent	mg/mL	mM
Solubility
	DMSO	3.6	10.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 359.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Gu M, Zhang Y, Zhou X, Ma H, Yao H, Ji F. Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines. Oncol Lett. 2014 Oct;8(4):1739-1744. doi: 10.3892/ol.2014.2354. Epub 2014 Jul 16. PMID: 25202402; PMCID: PMC4156221. 2. Tamaro I, Genazzani A, Canonico P, Grosa G. Lack of in vitro interactions using human liver microsomes between rabeprazole and anticancer drugs. Eur J Drug Metab Pharmacokinet. 2009 Jan-Mar;34(1):19-26. doi: 10.1007/BF03191379. PMID: 19462924. 3. Chen SQ, Hu BF, Yang YR, He Y, Yue L, Guo D, Wu TN, Feng XW, Li Q, Zhang W, Wen JG. The protective effect of rabeprazole on cisplatin-induced apoptosis and necroptosis of renal proximal tubular cells. Biochem Biophys Res Commun. 2022 Jul 5;612:91-98. doi: 10.1016/j.bbrc.2022.04.107. Epub 2022 Apr 25. PMID: 35512462. 4. Martínez-Pérez Y, Nequiz-Avendaño M, García-Torres I, Gudiño-Zayas ME, López-Velázquez G, Enríquez-Flores S, Mendoza E, Saavedra E, Pérez-Tamayo R, León-Avila G, Olivos-García A. Rabeprazole inhibits several functions of Entamoeba histolytica related with its virulence. Parasitol Res. 2020 Oct;119(10):3491-3502. doi: 10.1007/s00436-020-06868-0. Epub 2020 Sep 4. PMID: 32886229.

In vitro protocol:

In vivo protocol:

1. Chen SQ, Hu BF, Yang YR, He Y, Yue L, Guo D, Wu TN, Feng XW, Li Q, Zhang W, Wen JG. The protective effect of rabeprazole on cisplatin-induced apoptosis and necroptosis of renal proximal tubular cells. Biochem Biophys Res Commun. 2022 Jul 5;612:91-98. doi: 10.1016/j.bbrc.2022.04.107. Epub 2022 Apr 25. PMID: 35512462. 2. Martínez-Pérez Y, Nequiz-Avendaño M, García-Torres I, Gudiño-Zayas ME, López-Velázquez G, Enríquez-Flores S, Mendoza E, Saavedra E, Pérez-Tamayo R, León-Avila G, Olivos-García A. Rabeprazole inhibits several functions of Entamoeba histolytica related with its virulence. Parasitol Res. 2020 Oct;119(10):3491-3502. doi: 10.1007/s00436-020-06868-0. Epub 2020 Sep 4. PMID: 32886229.

1: Li X, Liu S, Yu M, Xi W, Wu X, Liu D, Liu A, Wang H. Simultaneous Determination of Multiple Acid-Suppressing Drugs by UPLC-MS/MS Method and Application for Pharmacokinetics Study. Drug Des Devel Ther. 2025 Feb 11;19:955-969. doi: 10.2147/DDDT.S493911. PMID: 39963602; PMCID: PMC11830758. 2: Kwon HY. So Many Choices, So Little Value: Potential Savings from Selecting Cost-Effective Proton Pump Inhibitors. Pharmacoecon Open. 2025 Feb 13. doi: 10.1007/s41669-025-00563-5. Epub ahead of print. PMID: 39948220. 3: Yu Z, Liu X, Qiao J, Shen W, Mao X, Lou G, Li Y, Xie Z, Ye J. Is Tailored Bismuth Quadruple Therapies (With Clarithromycin or Furazolidone) Based on Fecal Molecular Susceptibility Testing in First-Line Helicobacter pylori Eradication Treatment More Effective? A Three-Arm, Multicenter Randomized Clinical Trial. Helicobacter. 2025 Jan-Feb;30(1):e70018. doi: 10.1111/hel.70018. PMID: 39924352. 4: Krishnan A, Schneider CV, Walsh D. Proton pump inhibitors and all-cause mortality risk among cancer patients. World J Clin Oncol. 2025 Jan 24;16(1):99240. doi: 10.5306/wjco.v16.i1.99240. PMID: 39867734; PMCID: PMC11528898. 5: Ananthathandavan P, Narayanasamy D. Delineating CYP2C19-Mediated Interactions: Network Pharmacology Investigation of Ilaprazole and Clopidogrel versus Conventional Proton Pump Inhibitors. Curr Drug Discov Technol. 2024 Dec 31. doi: 10.2174/0115701638334244241224062453. Epub ahead of print. PMID: 39817374. 6: Xu X, Xu F, Chen J, Wang S, Wang X, Su B, Xu L, Lin J. Engineering of a (R)-selective Baeyer-Villiger monooxygenase to minimize overoxidation activity for asymmetric synthesis of active pharmaceutical prazoles. Int J Biol Macromol. 2025 Jan 8;296:139561. doi: 10.1016/j.ijbiomac.2025.139561. Epub ahead of print. PMID: 39793827. 7: Choi JP, Kim S, Park JS, Kim MS, Choi NK, Shin CM, Lee J. Utilization of Acid Suppressants After Withdrawal of Ranitidine in Korea: An Interrupted Time Series Analysis. J Prev Med Public Health. 2025 Jan;58(1):21-30. doi: 10.3961/jpmph.24.357. Epub 2024 Dec 30. PMID: 39788691; PMCID: PMC11824620. 8: Romano S, Rodrigues AT, Torre C, Perelman J. Patterns of outpatient proton‒pump inhibitors use among older adults in a duplicative health system: comparing public and private prescribing. BMC Health Serv Res. 2025 Jan 6;25(1):30. doi: 10.1186/s12913-024-12033-5. PMID: 39762802; PMCID: PMC11706009. 9: Zhang YJ, Duan DD, Tian QY, Wang CE, Wei SX. A pharmacovigilance study of the association between proton pump inhibitors and tumor adverse events based on the FDA adverse event reporting system database. Front Pharmacol. 2024 Dec 19;15:1524903. doi: 10.3389/fphar.2024.1524903. PMID: 39749203; PMCID: PMC11694325. 10: Nyenhuis DA, Watanabe SM, Tjandra N, Carter CA. Tsg101 mimicry of canonical E2 enzymes underlies its role in ubiquitin signaling. Proc Natl Acad Sci U S A. 2025 Jan 7;122(1):e2419542121. doi: 10.1073/pnas.2419542121. Epub 2024 Dec 31. PMID: 39739800; PMCID: PMC11725782. 11: Campagne O, Ilic K, Gabriel A, Sueda K, Ye R, Zhang F, Xu P, Ko HH, Sun K. A Phase 1, Open-Label, Randomized, Two-Part Study in Healthy Adult Volunteers to Evaluate the Bioavailability of the Maribavir Powder for Oral Suspension, as Well as Food Effect and Impact of Rabeprazole. Clin Pharmacol Drug Dev. 2025 Feb;14(2):133-143. doi: 10.1002/cpdd.1493. Epub 2024 Dec 22. PMID: 39711068. 12: Parveen S, Bhattacharya A, Silakari O, Sapra B. First report on QSAR modelling for chemical penetration enhancement ratio (ER) of different FDA- approved drugs in Poloxamer 407: A next step towards better skin permeability of drugs. Int J Pharm. 2025 Jan 25;669:125083. doi: 10.1016/j.ijpharm.2024.125083. Epub 2024 Dec 16. PMID: 39694159. 13: Liu C, Sun R, Wang H, Xia Y, Wang Y. Rabeprazole inhibits lung cancer progression by triggering NLRP3/CASP-1/caspase-dependent pyroptosis. Int Immunopharmacol. 2025 Jan 27;146:113806. doi: 10.1016/j.intimp.2024.113806. Epub 2024 Dec 15. PMID: 39681063. 14: Liu Y, Qu R, Zhao Y, Wang Z, Yuan S, Liu S, Zhou C, Yu J. Effectiveness of combined proton pump inhibitors and posaconazole prophylaxis against invasive fungal infections in patients with hematologic malignancies: a retrospective study. Int J Clin Pharm. 2024 Dec 7. doi: 10.1007/s11096-024-01841-8. Epub ahead of print. PMID: 39644376. 15: Faison SL, Batonga J, Arumugham T, Bartkus A, Morrison M, Mullin MJ, Tippin T, Naderer O. Relative Bioavailability of Dordaviprone (ONC201) is Not Affected by Co-Administration of the Proton-Pump Inhibitor Rabeprazole. J Clin Pharmacol. 2024 Nov 22. doi: 10.1002/jcph.6163. Epub ahead of print. PMID: 39577877. 16: Xie J, Liang X, Xie F, Huang C, Lin Z, Xie S, Yang F, Zheng F, Geng L, Xu W, Gong S, Xiang L. Rabeprazole suppressed gastric intestinal metaplasia through activation of GPX4-mediated ferroptosis. Front Pharmacol. 2024 Nov 7;15:1409001. doi: 10.3389/fphar.2024.1409001. PMID: 39575386; PMCID: PMC11578692. 17: Xie K, Li J, Tang C, Huang Z, Chen M. Association between proton pump inhibitors and dementia risk: a Mendelian randomization study. Sci Rep. 2024 Nov 19;14(1):28624. doi: 10.1038/s41598-024-79821-1. PMID: 39562663; PMCID: PMC11576989. 18: Li M, Yuan W, Kong X, Wu H, Cai Z, Zhu W, Lu X. Proton pump inhibitors reduce chemotherapeutic hepatotoxicity and enhance hepatic uptake and accumulation of drug-loaded extracellular vesicles. Sci Rep. 2024 Nov 15;14(1):28163. doi: 10.1038/s41598-024-75775-6. PMID: 39548145; PMCID: PMC11568174. 19: Jalihal U, Mahapatra JR, Kumar A, Bharadwaj T, Singh HD, Mehta V, Patil DR, Swami OC. Comparative Efficacy of Dexlansoprazole, Pantoprazole, Esomeprazole, and Rabeprazole in Achieving Optimal 24-Hour Intragastric pH Control: A Randomized Crossover Study Using Ambulatory pH Monitoring. Cureus. 2024 Oct 14;16(10):e71418. doi: 10.7759/cureus.71418. PMID: 39539895; PMCID: PMC11558283. 20: Setia A, Challa RR, Vallamkonda B, Vaishali, Viswanadh MK, Muthu MS. Clinical Implications of Proton Pump Inhibitors and Vonoprazan Micro/Nano Drug Delivery Systems for Gastric Acid-Related Disorders and Imaging. Nanotheranostics. 2024 Sep 30;8(4):535-560. doi: 10.7150/ntno.100727. PMID: 39507107; PMCID: PMC11539181.